Generated by AI
ANI Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and commercializes branded, generic, and specialty prescription medicines. ANI Pharmaceuticals focuses on three main areas: Rare Disease, Generics, and Established Brands. Its portfolio includes therapies for ophthalmology, rheumatology, nephrology, neurology, and pulmonology, alongside a broad range of generic products and established branded medicines. The company also supports contract manufacturing and pharmaceutical development services, leveraging U.S.-based manufacturing capabilities and expertise in complex formulations such as injectables, softgels, oral solids, liquids, and topical products. ANI Pharmaceuticals serves patients, pharmacies, wholesalers, specialty channels, and other healthcare customers through a diversified commercial model built around prescription pharmaceuticals and niche therapeutic markets.
Website210 Main Street West
Baudette, MN, 56623
United States
The latest articles about ANIP.
ANI Pharmaceuticals (ANIP) just put fresh numbers on the table, reporting third quarter and nine month 2026 results along with a slight trim to full year revenue guidance that gives investors new data to weigh. At a share price of $67.41, ANI Pharmaceuticals has slipped about 11% over the past 90 days and is down 14% year to date, while the 1 year total shareholder return is lower at 25% in decline. However, the 3 and 5 year total shareholder returns remain positive, suggesting that the...
Summary of May 8's posts. Generated by AI.
Summary of Nov 1's posts. Generated by AI.
Summary of Aug 8's posts. Generated by AI.
Investors talking about ANIP also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.